Botulinum neurotoxin type A (BoNT/A) is a metalloprotease that produces a sustained yet transitory blockade of transmitter release from peripheral nerve terminals. Local delivery of this neurotoxin is successfully employed in clinical practice to reduce muscle hyperactivity such as in spasticity and dystonia, and to relieve pain with long-lasting therapeutic effects. However, not all BoNT/A effects can be explained by an action at peripheral nerve terminals. Indeed, it appears that BoNT/A is endowed with trafficking properties similar to the parental tetanus neurotoxin and thus be able to directly affect the CNS. In this review, we present and discuss novel compelling evidence for a direct central effect of BoNT/A in both dorsal and ventral horns of the animal and human spinal cord after peripheral injection of the neurotoxin, with important consequences on pain and motor control. This new knowledge is expected to radically change the approach to the use of BoNT/A in the future. As BoNT/A central action appears to also contribute to functional improvement, for instance in human spastic gait, the challenge will be to develop new subtypes or BoNT derivatives with deliberate, cell-specific central effects in order to fully exploit the spectrum of BoNT/A therapeutic activity.
AkaikeNShinMCWakitaMToriiYHarakawaTGinnagaA, and others. 2013. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol591(Pt 4):1031–43.
2.
The influence of merged muscle excitation modules on post-stroke hemiparetic walking performance. Clin Biomech (Bristol, Avon)28(6):697–704.
3.
AntonucciFBozziYCaleoM. 2009. Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy. Epilepsia50(4):963–6.
4.
AntonucciFCerriCMaya VetencourtJFCaleoM. 2010. Acute neuroprotection by the synaptic blocker botulinum neurotoxin E in a rat model of focal cerebral ischaemia. Neuroscience169(1):395–401.
5.
AntonucciFRossiCGianfranceschiLRossettoOCaleoM. 2008. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci28(14):3689–96.
6.
AshkenaziABlumenfeldA. 2013. OnabotulinumtoxinA for the treatment of headache. Headache53(Suppl 2):54–61.
7.
AymardCGiboinLSLackmy-ValléeAMarchand-PauvertV. 2013. Spinal spasticity in stroke patients after botulinum neurotoxin A injection in ankle plantar flexors. Physiol Rep1(6):e00173.
8.
Bach-RojeckyLLackovicZ. 2009. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav94(2):234–8.
9.
Bach-RojeckyLSalkovic-PetrisicMLackovicZ. 2010. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol633(1-3):10–4.
10.
BadeSRummelAReisingerCKarnathTAhnert-HilgerGBigalkeH, and others. 2004. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem91(6):1461–72.
11.
BajohrsMRickmanCBinzTDavletovB. 2004. A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep5(11):1090–5.
12.
BannatyneBAEdgleySAHammarIJankowskaEMaxwellDJ. 2003. Networks of inhibitory and excitatory commissural interneurons mediating crossed reticulospinal actions. Eur J Neurosci18(8):2273–84.
13.
BenarrochEE. 2010. Central neuron-glia interactions and neuropathic pain: overview of recent concepts and clinical implications. Neurology75(3):273–8.
14.
BinzTRummelA. 2009. Cell entry strategy of clostridial neurotoxins. J Neurochem109(6):1584–95.
15.
BlerschWSchulte-MattlerWJPrzywaraSMayABigalkeHWohlfarthK. 2002. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci205(1):59–63.
16.
CaleoMAntonucciFRestaniLMazzocchioR. 2009. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?J Neurochem109(1):15–24.
17.
CaleoMRestaniLGianfranceschiLCostantinLRossiCRossettoO, and others. 2007. Transient synaptic silencing of developing striate cortex has persistent effects on visual function and plasticity. J Neurosci27(17):4530–40.
18.
CaleoMRestaniLVanniniESiskovaZAl-MalkiHMorganR and others. 2012. The role of activity in synaptic degeneration in a protein misfolding disease, prion disease. PLoS One7(7):e41182.
19.
CaleoMSchiavoG. 2009. Central effects of tetanus and botulinum neurotoxins. Toxicon54(5):593–9.
20.
CarrollIClarkJDMackeyS. 2009. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol65(3):348–51.
21.
ChaddockJAPurkissJRAlexanderFCDowardSFooksSJFriisLM, and others. 2004. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov Disord19(Suppl 8):S42–7.
22.
CioncoloniDTaddeiSBielliSAnnunziataPMazzocchioR. 2014. Meaningful improvement in walking performance after botulinum neurotoxin A (BoNT-A) in chronic spastic patients. NeuroRehabilitation34(1):185-192.
23.
ClarkDJTingLHZajacFENeptuneRRKautzSA. 2010. Merging of healthy motor modules predicts reduced locomotor performance and muscle coordination complexity post-stroke. J Neurophysiol103(2):844–57.
24.
ClowryGJWalkerLDaviesP. 2006. The effects of botulinum neurotoxin A induced muscle paresis during a critical period upon muscle and spinal cord development in the rat. Exp Neurol202(2):456–69.
25.
ColasanteCRossettoOMorbiatoLPirazziniMMolgoJMontecuccoC. 2013. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol48(1):120–7.
26.
CroneCJohnsenLLBiering-SorensenFNielsenJB. 2003. Appearance of reciprocal facilitation of ankle extensors from ankle flexors in patients with stroke or spinal cord injury. Brain126(Pt 2):495–507.
27.
CuiMKhanijouSRubinoJAokiKR. 2004. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107(1-2):125–33.
28.
DavletovBBajohrsMBinzT. 2005. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci28(8):446–52.
29.
de PaivaAMeunierFAMolgoJAokiKRDollyJO. 1999. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A96(6):3200–5.
30.
DietzV. 2003. Spinal cord pattern generators for locomotion. Clin Neurophysiol114(8):1379–89.
31.
DongMYehFTeppWHDeanCJohnsonEAJanzR and others. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science312(5773):592–6.
32.
DyerJOMaupasEde Andrade MeloSBourbonnaisDFleuryJForgetR. 2009. Transmission in heteronymous spinal pathways is modified after stroke and related to motor incoordination. PLoS One4(1):e4123.
33.
EleopraRTugnoliVRossettoODe GrandisDMontecuccoC. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett256(3):135–8.
34.
Favre-GuilmardCAuguetMChabrierPE. 2009. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 617(1-3):48–53.
35.
FerrariEGuCNiranjanDRestaniLRasetti-EscargueilCObaraI, and others. 2013. Synthetic self-assembling clostridial chimera for modulation of sensory functions. Bioconjug Chem24(10):1750–9.
36.
Gonzalez-ForeroDPastorAMGeimanEJBenitez-TeminoBAlvarezFJ. 2005. Regulation of gephyrin cluster size and inhibitory synaptic currents on Renshaw cells by motor axon excitatory inputs. J Neurosci25(2):417–29.
37.
HagenahRBeneckeRWiegandH. 1977. Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones. Naunyn Schmiedebergs Arch Pharmacol299(3):267–72.
38.
HesseSJahnkeMTLueckeDMauritzKH. 1995. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett201(1):37–40.
39.
HughesRWhalerBC. 1962. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol160:221–33.
40.
JackyBPGarayPEDupuyJNelsonJBCaiBMolinaY, and others. 2013. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog9(5):e1003369.
41.
KellerJENealeEAOylerGAdlerM. 1999. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett456(1):137–42.
42.
KerschensteinerDMorganJLParkerEDLewisRMWongRO. 2009. Neurotransmission selectively regulates synapse formation in parallel circuits in vivo. Nature460(7258):1016–20.
43.
KnikouM. 2008. The H-reflex as a probe: pathways and pitfalls. J Neurosci Methods171(1):1–12.
44.
KnikouMMummidisettyCK. 2011. Reduced reciprocal inhibition during assisted stepping in human spinal cord injury. Exp Neurol231(1):104–12.
45.
LapatkiBGvan DijkJPvan de WarrenburgBPZwartsMJ. 2011. Botulinum toxin has an increased effect when targeted toward the muscle’s endplate zone: a high-density surface EMG guided study. Clin Neurophysiol122(8):1611–6.
46.
MahrholdSRummelABigalkeHDavletovBBinzT. 2006. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett580(8):2011–4.
47.
Marchand-PauvertVAymardCGiboinLSDominiciFRossiAMazzocchioR. 2013. Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol591(Pt 4):1017–29.
48.
Marchand-PauvertVNielsenJB. 2002. Modulation of non-monosynaptic excitation from ankle dorsiflexor afferents to quadriceps motoneurones during human walking. J Physiol538(Pt 2):647–57.
49.
MarinelliSVaccaVRicordyRUggentiCTataAMLuvisettoSand others. 2012. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One7(10):e47977.
50.
MarquePSimonetta-MoreauMMaupasERoquesCF. 2001. Facilitation of transmission in heteronymous group II pathways in spastic hemiplegic patients. J Neurol Neurosurg Psychiatry70(1):36–42.
51.
MasuyerGChaddockJAFosterKAAcharyaKR. 2014. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol54:27–51.
52.
MatakIBach-RojeckyLFilipovicBLackovicZ. 2011. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience186:201–7.
53.
MatakIRiedererPLackovicZ. 2012. Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem Int61(2):236–9.
54.
MazzocchioRSpidalieriRDominiciFPopaTHallettMRossiA. 2007. Putative central effects of botulinum toxin, possibly mediated by changes in Renshaw cell activity, following intramuscular injection in humans. Movement Disord22:S36–7.
55.
McCreaDARybakIA. 2008. Organization of mammalian locomotor rhythm and pattern generation. Brain Res Rev57(1):134–46.
56.
MontalM. 2010. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem79:591–617.
57.
Moreno-LopezBPastorAMde la CruzRRDelgado-GarciaJM. 1997. Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology48(2):456–64.
58.
NeptuneRRClarkDJKautzSA. 2009. Modular control of human walking: a simulation study. J Biomech42(9):1282–7.
59.
PierCLChenCTeppWHLinGJandaKDBarbieriJT, and others. 2011. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett585(1):199–206.
60.
Pierrot-DeseillignyEBurkeD. 2005. The circuitry of the human spinal cord. New York: Cambridge University Press.
61.
RanouxDAttalNMorainFBouhassiraD. 2008. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol64(3):274–83.
62.
RestaniLAntonucciFGianfranceschiLRossiCRossettoOCaleoM. 2011. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci31(44):15650–9.
63.
RestaniLGiribaldiFManichMBercsenyiKMenendezGRossettoO, and others. 2012a. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog8(12):e1003087.
64.
RestaniLNovelliEBottariDLeonePBaroneIGalli-RestaL and others. 2012b. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic13(8):1083–9.
65.
RindHBButowtRvon BartheldCS. 2005. Synaptic targeting of retrogradely transported trophic factors in motoneurons: comparison of glial cell line–derived neurotrophic factor, brain-derived neurotrophic factor, and cardiotrophin-1 with tetanus toxin. J Neurosci25(3):539–49.
66.
SannaPPCelioMRBloomFERendeM. 1993. Presumptive Renshaw cells contain decreased calbindin during recovery from sciatic nerve lesions. Proc Natl Acad Sci U S A90(7):3048–52.
SchmiegNMenendezGSchiavoGTerenzioM. 2013. Signalling endosomes in axonal transport: Travel updates on the molecular highway. Semin Cell Dev Biol. Oct27 [Epub ahead of print]
69.
TanakaT. 1977. Synaptic activation of facial afferents on the facial neurons of the cat. Brain Res123(2):378–83.
70.
ToriiYKiyotaNSugimotoNMoriYGotoYHarakawaT, and others. 2011. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon57(1):93–9.
71.
TurkUIlhanSAlpRSurH. 2005. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol28(4):161–2.
72.
VaccaVMarinelliSEleuteriCLuvisettoSPavoneF. 2012. Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice. Brain Behav Immun26(3):489–99.
73.
VerderioCGrumelliCRaiteriLCocoSPaluzziSCaccinP and others. 2007. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic8(2):142–53.
74.
VintiMCostantinoFBayleNSimpsonDMWeiszDJGraciesJM. 2012. Spastic cocontraction in hemiparesis: effects of botulinum toxin. Muscle Nerve46(6):926–31.
75.
WangJZurawskiTHMengJLawrenceGOlangoWMFinnDP, and others. 2011. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem286(8):6375–85.
76.
WangJZurawskiTHMengJLawrenceGWAokiKRWheelerL, and others. 2012. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J26(12):5035–48.
77.
WhitemarshRCTeppWHBradshawMLinGPierCLScherfJM, and others. 2013. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun81(10):3894–902.
78.
WiegandHWellhonerHH. 1974. Type A botulinum toxin in cats: neural ascent and action on spinal cord reflexes. Naunyn Schmiedebergs Arch Pharmacol282:R106.
79.
WiegandHWellhonerHH. 1977. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol298(3):235–8.
80.
WindhorstU. 1996. On the role of recurrent inhibitory feedback in motor control. Prog Neurobiol49:517–87.
81.
WreeAMixEHawlitschkaAAntipovaVWittMSchmittO, and others. 2011. Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson’s disease. Neurobiol Dis41(2):291–8.
82.
XiaoLMackeySHuiHXongDZhangQZhangD. 2010. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med11(12):1827–33.
83.
YuanRYSheuJJYuJMChenWTTsengIJChangHH, and others. 2009. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology72(17):1473–8.
